🔔Stock Alerts via Telegram — Free for All Users

Stock Comparison

ABBV vs ECOR

AbbVie Inc vs electroCore, Inc.

The Verdict

ECOR takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed
Winner
ECOR

electroCore, Inc.

2.0

out of 10

Risk Trap

Head-to-Head

$403.8B

Market Cap

$53M
171.8

P/E Ratio

-3.8
N/A

Profit Margin

0.0%
N/A

Return on Equity

-447.9%
N/A

Debt-to-Equity

0.0
Moderate

Overall Risk

Aggressive
0.1

DVR Score

2.0

The Deep Dive

ABBV0.1/10

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Full ABBV Analysis
ECOR2.0/10

electroCore's gammaCore device targets a vast market for headache disorders with a patented, FDA-approved, non-invasive solution, demonstrating solid FY2025 revenue growth of 26% YoY to ~$32M and impressive gross margins of 86-87%. This strategic vision and operational efficiency are compelling. However, these positives are severely undermined by critical financial distress: a substantial GAAP net...

Full ECOR Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.